Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a condition that affects men and boys at various life stages, from puberty through to older adulthood. Whether you are researching gynecomastia in High Point NC or seeking to understand the condition more broadly, this article provides a comprehensive, clinically grounded overview. We cover the causes, diagnosis, and full range of treatment options, from conservative management to surgery, alongside clear guidance on when to seek medical advice and how to access appropriate support.

What Is Gynaecomastia and Who Does It Affect?

Gynaecomastia is benign glandular breast tissue enlargement in males, most common during puberty, neonatal life, and older adulthood, and is distinct from pseudogynaecomastia, which involves fat accumulation only.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia is the benign enlargement of glandular breast tissue in males, resulting in a noticeable swelling beneath one or both nipples. It is distinct from pseudogynaecomastia, which refers to fat accumulation in the chest area without true glandular growth — an important clinical distinction that guides management. The condition can affect males at any age, though it is particularly common during three key life stages:

• Neonatal period — due to maternal oestrogen exposure

• Puberty — affecting an estimated 50–70% of adolescent boys transiently, with most cases resolving spontaneously within six to twenty-four months

• Older adulthood — typically from the age of 50 onwards, as testosterone levels naturally decline

Despite being physically harmless in the majority of cases, gynaecomastia can carry a significant psychological burden. Many individuals report feelings of embarrassment, reduced self-confidence, and social withdrawal, particularly when the condition develops during adolescence.

Understanding the condition from a medical standpoint is the essential first step before exploring any intervention, whether conservative or surgical. Information in this article is aligned with UK clinical guidance, including that published by the NHS and the National Institute for Health and Care Excellence (NICE). For further reading, the NICE Clinical Knowledge Summary (CKS) on gynaecomastia and the NHS patient information page on enlarged male breasts provide authoritative, up-to-date guidance.

Common Causes of Enlarged Male Breast Tissue

Gynaecomastia results from an oestrogen-to-androgen imbalance caused by physiological changes, medications such as spironolactone or finasteride, or pathological conditions including hypogonadism, hyperthyroidism, or liver cirrhosis.

Gynaecomastia arises from an imbalance between oestrogen and androgen activity within breast tissue. Even though males produce small amounts of oestrogen naturally, any shift that increases the oestrogen-to-androgen ratio can stimulate glandular proliferation. Identifying the underlying cause is central to appropriate management.

Physiological causes account for the majority of cases and include:

• Hormonal fluctuations during puberty

• Age-related decline in testosterone in older men

• Transient neonatal gynaecomastia

Pathological causes are less common but clinically important to exclude. These include:

• Hypogonadism — primary or secondary testicular failure, including Klinefelter syndrome (47,XXY), which is associated with an increased risk of gynaecomastia

• Hyperthyroidism — elevated thyroid hormones can increase sex hormone-binding globulin (SHBG)

• Liver cirrhosis — impaired oestrogen metabolism

• Chronic kidney disease

• Adrenal or testicular tumours producing oestrogen or human chorionic gonadotrophin (hCG)

Medication-related gynaecomastia is a frequently overlooked cause. Drugs known to be associated with the condition include spironolactone, cimetidine, digoxin, anabolic steroids, anti-androgens used in prostate cancer treatment (such as bicalutamide), GnRH analogues, finasteride, dutasteride, certain antipsychotics, and some antiretrovirals (such as efavirenz). This list is not exhaustive; the British National Formulary (BNF) and individual medicine Summary of Product Characteristics (SmPC) documents, available via the electronic Medicines Compendium (emc), provide comprehensive information on medicines associated with this effect. If a medication is suspected as a contributing cause, it is important not to stop it without first consulting a healthcare professional, as abrupt discontinuation may carry its own risks.

Cannabis use has been reported in association with gynaecomastia; however, the evidence base is currently inconclusive and this association should be interpreted with caution.

Lifestyle factors such as obesity can contribute indirectly by increasing peripheral conversion of androgens to oestrogens within adipose tissue, further tipping the hormonal balance.

Diagnosing Gynaecomastia: What to Expect at Your Appointment

Diagnosis involves clinical examination, blood tests including testosterone and tumour markers, and testicular ultrasound where indicated; men aged 30 and over with an unexplained breast lump should be referred urgently via the two-week-wait pathway under NICE NG12.

A thorough clinical assessment is the cornerstone of diagnosing gynaecomastia. When attending an appointment — whether with a GP, an endocrinologist, or a specialist surgeon — the clinician will typically begin with a detailed medical history, including current medications, recreational drug use, alcohol consumption, and any family history of hormonal conditions.

Physical examination will focus on:

• Palpating the breast tissue to distinguish true glandular tissue (firm, rubbery, and centred beneath the nipple) from fatty tissue

• Assessing testicular size and consistency

• Checking for signs of systemic conditions such as liver disease or thyroid dysfunction

In cases where a pathological cause is suspected, the following investigations may be requested:

• Blood tests: serum testosterone (measured as an early-morning sample and repeated if low), luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, prolactin, thyroid function tests, liver function tests, and renal function. Where a pituitary or genetic cause is suspected, further specialist testing may be arranged.

• Tumour markers: serum beta-human chorionic gonadotrophin (beta-hCG) and alpha-fetoprotein (AFP) should be measured when a testicular germ cell tumour is suspected.

• Testicular ultrasound: to exclude a testicular tumour, particularly if the testes feel abnormal on examination or tumour markers are raised. This should be arranged urgently in such cases.

• Mammography or breast ultrasound: occasionally used to differentiate gynaecomastia from rarer conditions such as male breast cancer, which, whilst uncommon, must be excluded when there is a hard, eccentric, or rapidly growing mass.

In line with NICE guideline NG12 (Suspected cancer: recognition and referral), clinicians should refer men aged 30 and over with an unexplained breast lump urgently via the two-week-wait pathway. For men of any age presenting with suspicious features — such as a hard, fixed, or rapidly enlarging lump, nipple changes, skin changes, or nipple discharge — urgent referral for specialist assessment should be considered. Men aged 50 and over with unilateral nipple changes (discharge, retraction, or other nipple abnormality) should also be referred urgently. In the majority of cases, however, investigations confirm a benign, physiological, or medication-related aetiology, and reassurance forms a significant part of the management plan.

Further detail on assessment and investigations is available in the NICE CKS on gynaecomastia.

Treatment Options Available for Gynaecomastia

Treatment ranges from addressing the underlying cause and watchful waiting to off-label SERMs such as tamoxifen in early active disease, or subcutaneous mastectomy for longstanding, distressing gynaecomastia unresponsive to conservative measures.

The appropriate treatment for gynaecomastia depends on its underlying cause, duration, severity, and the degree of distress it causes the individual. Many cases — particularly those arising during puberty — resolve spontaneously within six to twenty-four months without any specific intervention.

Conservative management is the first-line approach in most cases and includes:

• Addressing the underlying cause (e.g., adjusting or substituting a causative medication under medical supervision)

• Weight management, where obesity is a contributing factor

• Reassurance and psychological support, particularly for adolescents

Pharmacological treatment is not routinely recommended by NICE for gynaecomastia but may be considered in specific circumstances, particularly during the early, active phase of glandular growth (generally within the first six to twelve months). Options that have been used off-label in the UK include:

• Tamoxifen (a selective oestrogen receptor modulator, or SERM) — evidence suggests modest benefit in reducing breast volume and tenderness. When used by specialists, a typical regimen is tamoxifen 10–20 mg daily for up to three months, though practice may vary.

• Raloxifene — an alternative SERM with a similar mechanism, used in some specialist centres.

• These medications are not licensed specifically for gynaecomastia in the UK and should only be prescribed by a specialist following careful risk-benefit discussion. Key risks include venous thromboembolism (VTE), hot flushes, and other SERM-class effects; full prescribing information is available in the BNF and via emc SmPCs for tamoxifen and raloxifene.

• Aromatase inhibitors (e.g., anastrozole) and danazol are generally not recommended for gynaecomastia due to limited evidence of benefit and a less favourable adverse effect profile.

If you experience unexpected symptoms whilst taking any medicine for gynaecomastia, you can report these to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card scheme (yellowcard.mhra.gov.uk).

Surgical treatment is considered when gynaecomastia is longstanding, causing significant psychological distress, or has not responded to conservative measures. Surgical options include:

• Subcutaneous mastectomy — removal of glandular tissue, often combined with liposuction

• Liposuction alone — suitable where pseudogynaecomastia predominates

NHS funding for surgery is not routinely available for cosmetic indications alone; access depends on local Integrated Care Board (ICB) policies and defined clinical thresholds. Individuals should discuss eligibility with their GP. Those seeking surgical correction privately should ensure their surgeon is registered with the General Medical Council (GMC), that the facility is registered with the Care Quality Commission (CQC), and should consider choosing a surgeon who is a member of the British Association of Aesthetic Plastic Surgeons (BAAPS) or the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS), both of which publish patient information on gynaecomastia surgery.

When to Seek Medical Advice About Chest Changes

Seek prompt GP assessment for hard, fixed, or eccentric lumps, nipple discharge, skin changes, or axillary swelling, as these features may indicate male breast cancer requiring urgent investigation under NICE NG12.

Whilst gynaecomastia is most commonly benign, certain features warrant prompt medical evaluation. It is important not to dismiss chest changes in males as automatically insignificant, as early assessment ensures that serious conditions are not overlooked.

Contact your GP promptly if you notice:

• A lump that is hard, fixed, or not centred beneath the nipple

• Rapid or one-sided breast enlargement

• Nipple discharge, particularly if bloodstained

• Skin changes over the breast, such as dimpling, puckering, or ulceration

• New swelling or lumps in the armpit (axillary lymphadenopathy)

• Associated symptoms such as unexplained weight loss, fatigue, or testicular changes

These features may indicate male breast cancer or an underlying systemic condition requiring urgent investigation. In line with NICE NG12, men aged 30 and over with an unexplained breast lump should be referred urgently via the two-week-wait pathway; men of any age with suspicious features should receive prompt specialist assessment. Although male breast cancer is rare — accounting for less than 1% of all breast cancer diagnoses in the UK — delayed presentation is associated with poorer outcomes. The NHS breast cancer symptoms page provides further patient-facing guidance on red flag features.

For adolescents, parents or carers should seek a GP review if breast enlargement persists beyond two years, is causing significant distress, or is accompanied by delayed puberty or other signs of hormonal imbalance. For adult men, any new or changing breast lump should be assessed clinically rather than assumed to be benign.

It is also advisable to seek advice if you suspect a prescribed medication may be contributing to breast changes. A GP or pharmacist can review your medication list and, where appropriate, explore alternatives — but it is essential not to stop any prescribed treatment without professional guidance.

Living With Gynaecomastia: Support and Next Steps

Practical support includes compression vests, weight management, and psychological therapies such as CBT via NHS Talking Therapies; surgical correction should only follow exclusion of underlying causes and consultation with a GMC-registered surgeon at a CQC-registered facility.

For many individuals, living with gynaecomastia — particularly when it is longstanding or resistant to treatment — can affect quality of life in ways that extend well beyond the physical. Body image concerns, avoidance of activities such as swimming or sport, and difficulties with intimacy are commonly reported. Acknowledging these challenges is an important part of holistic care.

Practical steps that may help include:

• Wearing well-fitted, supportive clothing or compression vests to reduce the visual appearance of breast tissue; ensure any garment fits correctly and does not cause discomfort or restrict breathing

• Engaging in regular physical activity and maintaining a healthy weight, which can reduce the contribution of adipose tissue

• Speaking openly with a trusted GP or specialist about the emotional impact of the condition

Psychological support may be beneficial for those experiencing significant distress, low self-esteem, or symptoms consistent with body dysmorphic disorder (BDD). Referral to a mental health professional can be arranged through your GP. NHS Talking Therapies (formerly IAPT, available in England) offers evidence-based psychological therapies, including cognitive behavioural therapy (CBT), for anxiety and depression. Where symptoms suggest BDD or obsessive-compulsive disorder, NICE guideline CG31 provides relevant guidance on assessment and treatment pathways.

For those considering surgical correction, it is advisable to:

• Ensure all underlying medical causes have been excluded or treated first

• Allow adequate time for spontaneous resolution, particularly in younger patients

• Consult with a GMC-registered plastic or breast surgeon, operating from a CQC-registered facility, who can provide a thorough assessment and realistic expectations; BAAPS and BAPRAS publish helpful patient information on what to expect from gynaecomastia surgery

Ultimately, gynaecomastia is a manageable condition. With the right medical support, accurate diagnosis, and access to appropriate treatment — whether conservative, pharmacological, or surgical — most individuals are able to achieve a satisfactory outcome. The first and most important step is an open, honest conversation with a qualified healthcare professional.

Useful UK resources:

• NICE CKS: Gynaecomastia (primary care assessment and management)

• NICE NG12: Suspected cancer — recognition and referral

• NHS: Gynaecomastia (enlarged male breasts)

• NHS Talking Therapies: www.nhs.uk/mental-health/talking-therapies-medicine-treatments/talking-therapies-and-counselling/nhs-talking-therapies

• MHRA Yellow Card scheme: yellowcard.mhra.gov.uk

• BAAPS / BAPRAS patient information on gynaecomastia surgery

Frequently Asked Questions